In This Issue
Cancer Discov July 1 2013 3 (7) 705-708; DOI:10.1158/2159-8290.CD-ITI13-07
An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.
The receptor tyrosine kinase RON suppresses antitumor immune responses to promote metastatic outgrowth and is a potential therapeutic target to inhibit metastasis.
PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.
Gene expression, copy number, methylation, and mutation analyses implicate Notch deregulation in oral squamous cell carcinoma and identify potentially actionable events.
Inhibition of diacylglycerol kinase α downregulates oncogenic pathways including HIF-1α and mTOR and is selectively toxic to glioblastoma and other cancer cells.
ZNF365 is a p53-inducible gene product that maintains genomic stability by preventing recombination of defective telomere ends and common fragile site abnormalities.
SNPs related to ZNF423 and CTSO are associated with breast cancer risk during SERM therapy, and these genes promote estrogen-dependent induction of BRCA1 transcription in an SNP-dependent fashion.